食管鳞状细胞癌中MCM2蛋白与Ki-67的表达及对比研究

目的 探讨微小染色体维持蛋白2(minichromosome maintenance 2 protein,MCM2)与Ki-67在食管癌中的表达及两者表达的差异和相关性.方法 采用免疫组化EliVision方法,分别检测90例食管鳞状细胞癌组织中MCM2,Ki-67的表达,计算其标记指数(labeling index,LI),分析MCM2,Ki-67在食管鳞癌中的表达及两者之间的差异和相关性.结果 90例食管癌组织均表达MCM2及Ki-67抗原,其中MCM2 LI高于Ki-67,两者差异有统计学意义(P＜0.05).同时显示MCM2及Ki-67的表达与食管鳞癌的分化程度具有相关性,MCM2在食管鳞癌各级组织间表达差异均有统计学意义(P＜0.01),而Ki-67只在Ⅰ级与Ⅲ级食管鳞癌组织间差异有统计学意义(P＜0.01).并且MCM2与Ki-67在食管鳞癌中的表达呈正相关关系(P＜0.01).结论 MCM2是优于Ki-67的细胞增殖标记物,可用于对食管鳞癌的分级和判断食管鳞癌恶性程度的高低.     

乳腺癌中胸苷激酶1的表达及其临床意义

目的 观察胸苷激酶1(TK1)在乳腺癌组织中的表达情况,与临床病理因素及ER、PR、p53、c-erbB-2、Ki-67等乳腺癌相关因子的关系.方法 对100例乳腺癌组织标本进行常规HE染色检查,明确其组织学类型、病理特点及临床分期,应用免疫组化MaxVison法检测乳腺癌组织中ER、PR、p53、c-erbB-2、Ki-67及TK1的表达情况.结果 乳腺癌组织中TK1阳性表达主要位于细胞质,部分细胞核有表达.在100例乳腺癌中,TKl的阳性率为85%(85/100),TKl表达在组织学分级、TNM分期中差异有显著性(P均＜0.05).TKl表达与Ki-67表达(r=0.871)有正相关性,与ER表达(r=-0.374)及PR表达(r=-0.384)有负相关性.结论 TKl在乳腺癌中的表达在不同组织学分级、TNM分期中存在差异,组织学分级及TNM分期越高,TK1的表达也就越高,TK1是一个灵敏的反应乳腺癌细胞增殖的指标.TK1在乳腺癌中的表达与Ki-67、ER、PR的表达有相关性,TKl表达水平越高,Ki-67的阳性率也越高,而ER、PR表达水平则降低.     

Ki-67表达与乳腺癌分子分型及临床病理特征的关系

目的：观察不同分子亚型乳腺癌中Ki-67的表达及其与乳腺癌临床病理特征的关系及意义。方法采用免疫组化En-Vision两步法检测245例乳腺癌组织中ER、PR、HER-2及Ki-67的表达,并比较Ki-67表达与乳腺癌临床病理参数的关系。结果不同分子分型乳腺癌中Ki-67的增殖指数差异有统计学意义( P<0．05);有淋巴结转移及肿块较大者中Ki-67增殖指数高于无淋巴结转移及肿块较小者,ER、PR阳性者中Ki-67增殖指数低于ER、PR阴性者,差异有统计学意义;患者按中位年龄50岁进行分组时,≤50岁组与>50岁组的Ki-67增殖指数差异无统计学意义;患者按≤40岁及≥60岁分为年轻组及老年组时,年轻组Ki-67增殖指数明显高于老年组。结论 Ki-67在三阴型乳腺癌、年轻患者、伴腋窝淋巴结转移、肿块较大及ER、PR阴性组中的增殖指数较高。 Ki-67可作为判断乳腺癌预后的重要指标。     

胃肠道间质瘤中Ki-67表达及其与临床病理特征、危险度分级的相关性

目的探讨Ki-67在胃肠道间质瘤(gastrointestinal stromal tumors,GIST)中的表达及其与临床病理特征、危险度分级的相关性。方法分析77例手术切除的原发性GIST患者的临床病理资料,采用免疫组化SP法检测Ki-67的表达,分析其表达与GIST的临床病理特征及危险度分级的相关性。结果Ki-67表达在肿瘤部位、核分裂象、危险度分级中,差异有统计学意义(P0.05);在患者年龄、性别、肿瘤大小、组织类型、囊性变、单发或多发、出血、坏死及合并其他肿瘤中,差异无统计学意义(P0.05);Ki-67增殖指数与肿瘤部位、核分裂象、单发或多发及危险度分级有相关性(P0.05),其中Ki-67增殖指数与核分裂象及危险度分级呈正相关。结论Ki-67增殖指数可作为判断GIST危险度分级及预后预测的重要参考指标。     

WNT5B在乳腺癌中的表达及意义

目的:研究WNT5B在乳腺癌中的表达,初步探讨WNT5B与乳腺癌临床病理特征的关系。方法:采用real-time PCR和Western blot法检测67例乳腺癌及癌旁组织中WNT5B在mRNA和蛋白水平的表达情况,通过免疫组织化学方法检测WNT5B在乳腺癌和癌旁组织中的表达并分析WNT5B的表达与相关临床病理指标之间的关系。结果:67例乳腺癌组织标本中均有不同程度WNT5B的mRNA及蛋白表达,且WNT5B在乳腺癌组织的表达明显低于癌旁组织(P0.05);其中WNT5B在原发性肿瘤大小T≤20 mm的乳腺癌患者中的表达明显高于其在T20 mm组患者中的表达(P0.05);WNT5B的表达与乳腺癌患者腋窝淋巴结转移情况、组织学分级、相关的免疫组织化学指标(ER、PR、c-Er Bb-2、p53和Ki-67)之间无明显的相关性(P0.05)。结论:WNT5B在乳腺癌组织中的表达低于癌旁组织,WNT5B表达与乳腺癌患者原发肿瘤大小呈负相关,提示WNT5B可能作为乳腺癌预后的一个新的分子标志物,为乳腺癌的诊治提供新的思路。     

乳腺癌组织中SOX4、EZH2的表达及临床意义

目的观察上皮-间质转化(epithelial-mesenchymal transition,EMT)调控因子SOX4和EZH2在乳腺癌组织中的表达,探讨两者的临床意义。方法采用免疫组化En Vision两步法检测241例乳腺癌组织及126例癌旁非肿瘤乳腺组织中SOX4、EZH2的表达,分析两者表达的相关性及其与乳腺癌临床病理特征的关系。结果乳腺癌组织中SOX4的高表达率为82.2%,显著高于癌旁非肿瘤乳腺组织的高表达率(57.1%,P0.05);EZH2在乳腺癌组织中的高表达率为80.1%,显著高于癌旁非肿瘤乳腺组织的高表达率(47.6%,P0.05)。SOX4高表达与肿瘤淋巴结转移、TNM高分期、HER-2高表达相关(P0.05);EZH2高表达与肿瘤组织学高分级、淋巴结转移、ER阴性、EGFR阳性、Ki-67高增殖指数相关(P0.05),并与SOX4表达呈显著正相关(rs=0.256,P0.001)。结论 EMT调控因子SOX4和EZH2在乳腺癌组织中表达上调,两者可能共同参与乳腺癌的转移,有望成为预测乳腺癌转移的潜在生物学标志物。     

Ki-67和PCNA表达与乳腺癌及乳腺癌化疗敏感性的关系

目的:探讨分析乳腺癌组织中核增殖相关抗原(Ki-67)及增殖细胞核抗原(PCNA)表达变化与乳腺癌的关系及其对乳腺癌化疗敏感性的关系,为临床乳腺癌的有效化疗提供理论依据。方法:实验对象取自于近年来我院收治的、经临床检查确诊为乳腺癌患者84例,利用免疫组化方法分别测量其乳腺癌组织中的Ki-67及PCNA的含量,比较不同Ki-67及PCNA表达水平的患者接受化疗疗效的差异。结果:Ki-67阳性例数为52例,PCNA阳性例数为62例。Ki-67阳性率与患者淋巴结转移及肿瘤分型分期呈正相关,差异有统计学意义,P<0.05。而PCNA阳性率与肿瘤淋巴结转移成正相关,P<0.05,与肿瘤临床分型分期无关,P>0.05。Ki-67+总有效率为80.8%明显高于Ki-67-的56.2%,P<0.05。PCNA-有效率为72.7%明显高于PCNA+的45.2%,P<0.05。结论:Ki-67及PCNA表达与乳腺癌临床资料及其化疗敏感性密切相关,可以作为预测化疗疗效的指标。     

宫颈鳞状上皮内病变与EBP50、p16和Ki-67表达的相关性分析

目的:评价Ezrin-radixin-moesin结合磷酸化蛋白50(Ezrin-radixin-moesin binding phosphoprotein 50,EBP50)、p16和Ki-67在正常宫颈组织和宫颈鳞状上皮内病变(Squamous intraepithelial lesion,SIL)中的表达及临床意义.方法:选取2018年10月至2020年06月正常宫颈组织21例、SIL组织80例,采用免疫组化方法检查EBP50、p16和Ki-67表达水平,通过相关性检验分析EBP50与p16、Ki-67表达的相关性.结果:EBP50在正常宫颈组织中表达明显高于SIL(P=0.000);SIL中p16和Ki-67表达显著高于正常宫颈组织中的表达(P=0.000);高级别鳞状上皮内病变(High-grade squamous intraepithelial lesion,HSIL)EBP50表达强度比低级别鳞状上皮内病变(Low-grade squamous intraepithelial lesion,LSIL)降低(P=0.003);EBP50与p16或Ki-67的表达在SIL中呈负相关.结论:EBP50、p16和Ki-67的检测对SIL的病理诊断具有参考价值.EBP50表达的降低与宫颈病变的级别升高相关,EBP50可作为判断SIL分级的有效辅助手段.     

乳腺癌中IMP3表达及其与临床病理特征的关系

目的研究乳腺癌中IMP3的表达及其与临床病理特征之间的关系。方法利用组织芯片技术和免疫组织化学EliVi-sion两步法检测214例乳腺癌标本中IMP3的表达。结果214例乳腺浸润性导管癌中,IMP3阳性表达31例(14.49%)。乳腺癌IMP3的阳性表达与乳腺癌的组织学级别(P=0.005)、Ki-67增殖指数(P=0.033)及三阴性表型(P0.001)密切相关。IMP3的表达与病人年龄、肿瘤最大直径、淋巴结转移数量、pTNM分期和p53表达状况均无关(P0.05)。结论IMP3表达与乳腺癌组织级别高、Ki-67增殖指数高以及在三阴性亚组表达高相关,预示IMP3与乳腺癌的进展和恶性度相关,并可能作为三阴性乳腺癌的一个辅助诊断指标。     

乳腺癌中INHBA表达及与临床预后的关系

目的检测INHBA(inhibin-βA)在乳腺癌及癌旁乳腺组织中的表达,探讨其与乳腺癌临床病理特征的关系及对乳腺癌患者预后的意义。方法应用免疫组化法检测85例乳腺浸润性导管癌及35例癌旁乳腺组织中INHBA的表达。结果INHBA在乳腺癌和癌旁组织中的表达差异有统计学意义(P0.05)。INHBA高表达和肿瘤较低的分化程度、淋巴结转移及较高的Ki-67增殖指数具有相关性(P0.05)。INHBA高表达乳腺癌患者的生存期明显短于低表达组(P0.05)。多因素Cox比例风险回归模型分析显示,INHBA表达可以作为判断乳腺癌患者的独立危险因素(P0.05)。结论INHBA表达与肿瘤分化程度、淋巴结转移及Ki-67增殖指数密切相关,可能参与乳腺癌的发生发展,可以作为乳腺癌患者预后的判断指标。     

MCM2 and Ki-67 expression in human lung adenocarcinoma: prognostic implications.

OBJECTIVE: The expressions of minichromosome maintenance protein 2 (MCM2), Ki-67, and p53 were examined to analyze their pathobiological significance in human lung adenocarcinomas. METHODS: We performed Western blot analysis in six human lung adenocarcinoma cell lines and immunohistochemistry in 145 surgically removed adenocarcinomas to examine the MCM2 expression. Labeling indices (LIs; %) of MCM2, Ki-67, and p53 in the tumor cells were compared with clinicopathological profiles and overall survival rates. RESULTS: MCM2 protein was detected in all cell lines examined, with specific bands. MCM2 LIs were significantly correlated with sex, histological type, differentiation, pathological stage, and LIs of Ki-67 and p53 (p < 0.05). Significantly higher LIs of MCM2 and Ki-67 were noted in the 122 non-pure bronchioloalveolar carcinomas than in the 23 pure bronchioloalveolar carcinomas (p < 0.01), and the prognosis was poorer in the former than in the latter (p < 0.01). Sex, pathological stage, and high LIs of MCM2 and/or Ki-67 were independent prognostic factors (p < 0.05). CONCLUSION: High LIs of MCM2 and/or Ki-67 suggest a poor prognosis in patients with lung adenocarcinoma (non-pure bronchioloalveolar carcinoma).     

Relationship of p53, Bcl-2, Ki-67 index and E-cadherin expression in early invasive breast cancers with comedonecrosis as an accelerated apoptosis

AIMS: To study the relationship between comedonecrosis formation and morphology, apoptosis, and p53, Bcl-2, Ki-67 index and E-cadherin expression in early invasive breast cancer. Experimental design: Early invasive breast cancers were first divided into two groups according to the presence (CN+ tumours) or absence (CN- tumours) of comedonecrosis. The histological grade, apoptosis, and expression of E-cadherin, Ki-67, p53 and Bcl-2 in the cancer-affected area, and in normal ducts from the specimen, were then examined. RESULTS: Less tubule and gland formation was seen in CN+ tumours than in CN- tumours, although the histological grade between the groups was not different. During early comedonecrosis, cells undergo apoptosis and subsequent necrosis. p53 was higher in CN+ tumours than in CN- tumours and normal ducts, whereas Bcl-2 was lower in CN+ tumours than in CN- tumours and normal ducts. Both tumours had higher Ki-67 than in normal ducts, but no difference was evident between the tumours. CN+ tumours had slightly higher E-cadherin than that in CN- tumours, but lower than that in normal ducts. The level of comedonecrosis was positively correlated with p53, but inversely correlated with Bcl-2 in all tumours, and p53 and Bcl-2 were inversely correlated with each other. Furthermore, comedonecrosis and p53 were correlated with Ki-67 in CN+ tumours, and Bcl-2 was correlated with Ki-67 in CN- tumours. CONCLUSION: Comedonecrosis may be actively regulated through an apoptotic procedure in massive cancers for their survival and progression, and the above proteins may be associated cooperatively in this process. CN+ and CN- tumours may have opposite proliferative systems under the p53-Bcl-2 pathway.     

Minichromosome maintenance protein 3 is a candidate proliferation marker in papillary thyroid carcinoma

The proliferative capacity of tumor cells is a characteristic feature in the whole growing tumors. Many pathologists and clinicians have used the estimation of cell proliferation for prognostic information. Minichromosome maintenance protein 3 (MCM3) is known to have a role on the initiation and regulation of DNA replication during cell cycle. The aim of this study was to evaluate the potential applicability of one of the MCM proteins, MCM3, as a proliferation marker in papillary thyroid carcinoma (PTC) with correlation to clinicopathological parameters. We performed the immunohistochemical analysis for MCM3 and Ki-67 in 60 cases of PTC and Western blot analysis for MCM3 expression in 6 PTCs and normal thyroid tissues. The comparison of MCM3 labeling index (LI) to tumor size (P = 0.031) and extrathyroidal extension (P = 0.037) was statistically significant while that of Ki-67 LI to them was not. Moreover, a significant association was not observed between MCM3 and Ki-67, but the MCM3 LI was considerably higher. Western blot analyses revealed that the MCM3 protein expression levels were overexpressed in all PTCs. On the contrary, the levels of MCM3 were very low or absent in all normal thyroid tissues. Our results indicate that MCM3 may be a more reliable proliferation marker than Ki-67 in accessing the growth of tumor and evaluating tumor aggressiveness of PTC.     

Immunohistochemical analysis of bcl-2 and p53 expression in breast carcinomas: their correlation with Ki-67 growth fraction

We examined 59 breast cancers for p53 and bcl-2 protein expression by immunohistochemistry. The results were correlated with Ki-67 immunostaining. p53-negativity was noted in 40 cases and the remaining 19 tumours were p53-positive. Thirty-six tumours showed strong expression of bcl-2 and in 23 no staining for this protein was observed. We found statistically significant reverse correlation between expression of p53 and bcl-2 in majority of carcinomas: 31 cases were bcl-2 positive and p53-negative, and 14 tumours were bcl-2-negative and p53-positive. Six carcinomas showed no nuclear staining for Ki-67 and in the remaining 53 the percent of cancer cells positive for Ki-67 ranged from 1 to 60 (mean: 14.6). In these 53 cases we found that bcl-2-positive tumours were characterized by lower proliferation than bcl-2-negative tumours, the mean value of Ki-67 immunostaining being 10.7% and 23.0%, respectively. p53-negative tumours showed lower proliferation than p53-positive tumours: mean Ki-67 index was 10.2% and 23.9%, respectively.We conclude that immunohistochemically detected p53 and bcl-2 proteins show a significant inverse relationship in majority of breast carcinomas and their expression correlates with tumour proliferation (Ki-67 immunostaining).     

Expression of cyclooxygenase-2, p53 and Ki-67 in gastric cancer

It has been reported that p53 mutation may contribute to upregulate cyclooxygenase (COX)-2 expression that is observed in malignant tissues. These molecules are involved in carcinogenesis by affecting tumor cell proliferation. The aim of this study was to examine the relationship between COX-2 or p53 expression and clinico-pathological characteristics including tumor cell proliferation in gastric cancer. COX-2 and p53 expressions were investigated with immunostaining, in tissue specimens obtained from 119 patients who underwent surgery for gastric cancer. The Ki-67 labeling index (LI) was counted by Ki-67 immunostaining. COX-2 and p53 expressions correlated significantly with depth of tumor invasion. However, there was no association between COX-2 or p53 expression and survival. p53 expression did not correlate with COX-2 expression. There was no significant difference in various clinicopathological variables between Ki-67 LI subgroups. The mean Ki-67 LI value of COX-2 positive tumors was significantly higher than that of negative tumors. The mean Ki-67 LI value of p53 positive tumors was not significantly higher than that of negative tumors. The mean Ki-67 LI value of both COX-2 and p53 positive tumors was significantly higher than that of both negative tumors. These results imply that COX-2 expression is associated with tumor cell proliferation of gastric cancer.     

miR-342-3p 在乳腺癌中的表达及其与临床病理特征、 远期预后的相关性

目的研究 miR-342-3p 在乳腺癌中表达及其与临床病理特征、 远期预后的相关性。方法选择 2014 年 1 月 ~ 2015 年 2 月期间在南平市第一医院接受乳腺癌根治术的患者作为乳腺癌组, 同期接受手术切 除的乳腺良性肿瘤患者作为对照组, 检测乳腺癌组织及乳腺良性肿瘤组织中 miR-342-3p 的表达水平, 随访 乳腺癌患者的总生存 (OS) 及无病生存 (DFS), 采用 Kaplan-Meier 曲线分析 miR-342-3p 的表达水平与 OS、 DFS 的关系, 采用 COX 比例风险模型分析 OS、 DFS 的影响因素。 在乳腺癌 MCF7 细胞中转染 miR-NC 序列及 miR-342-3p 模拟物, 检测细胞活力水平及 AKT2、 Bcl2L1、 FOXQ1 的表达水平。结果乳腺癌组织 中 miR-342-3p 的表达水平明显低于乳腺良性肿瘤组织 (P< 0. 05), 且不同 T 分期、 淋巴结转移、 分子分 型、 Ki-67 表达的乳腺癌组织间比较, miR-342-3p 表达水平有显著差异 (P< 0. 05)。 Kaplan-Meier 曲线分析 显示, 相比于 miR-342-3p 高表达患者, miR-342-3p 低表达患者的 DFS 和 OS 均缩短。 COX 比例风险模型分 析显示, 淋巴结转移、 Ki-67 表达、 miR-342-3p 表达是乳腺癌患者 DFS 和 OS 的影响因素。 miR-342-3p 高表 达的乳腺癌组织中 AKT2、 Bcl2L1、 FOXQ1 的表达水平低于 miR-342-3p 低表达的乳腺癌组织。 miR-342-3p 组 MCF7 细胞中细胞活力及 AKT2、 Bcl2L1、 FOXQ1 的表达水平均低于 miR-NC 组。结论乳腺癌中 miR-342-5p 低表达且其低表达与病理特征恶化有关, miR-342-5p 低表达是乳腺癌患者预后的影响因素, AKT2、 Bcl2L1、 FOXQ1 可能是 miR-342-5p 参与乳腺癌发展的潜在分子机制。     

乳腺浸润性导管癌中ER、PR、Her-2、Ki-67表达与病理特征及预后的相关性

目的 探究Ki-67、ER、PR、Her-2等基因在乳腺浸润性导管癌（IDC）组织中的表达,分析其与患者临床病理特征及预后的相关性。方法 收集2013年1月~2014年12月广东医科大学附属医院病理科乳腺包埋石蜡块IDC组织74例。采用免疫组织化学法检测ER、PR、Her-2、Ki-67在IDC组织中的表达,分析其与患者年龄、组织学分级、TNM分期、淋巴结转移及预后的相关性。结果 ①不同年龄、组织学分级、淋巴结转移及TNM分期的IDC患者ER、PR表达情况比较,差异均无统计学意义（P＞0.05）;未发生淋巴结转移的IDC患者Her-2表达低于转移患者,差异有统计学意义（P＜0.05）;不同年龄、组织学分级、TNM分期的IDC患者Her-2表达比较,差异无统计学意义（P＞0.05）;不同TNM分期的IDC患者Ki-67表达情况比较,差异有统计学意义（P＜0.05）,不同年龄、组织学分级、淋巴结转移的IDC患者Ki-67表达比较,差异均无统计学意义（P＞0.05）。 ②Spearman相关性分析显示,ER与PR正相关,ER与Her-2、PR与Her-2负相关,ER、Ki-67和PR、Ki-67负相关,Her-2与Ki-67正相关。③Ki-67阳性表达的IDC患者病死率高于Ki-67阴性表达的患者,差异有统计学意义（P＜0.05）;不同ER、PR、Her-2表达情况的IDC患者病死率比较,差异无统计学意义（P＞0.05）;Ki-67阴性表达患者的总生存时间（OS）高于阳性表达患者,COX多因素分析显示,Ki-67阳性表达是影响IDC患者OS的独立因素（95%CI:0.212~0.865,P=0.018）。结论 Ki-67可作为乳腺浸润性导管癌危险评估的分子标志物,其阳性表达可影响乳腺癌患者的预后。ER、PR、Her-2的表达对乳腺浸润性导管癌患者的预后没有明显影响。     

Expression of minichromosome maintenance 2 (MCM2), Ki-67, and cell-cycle-related molecules, and apoptosis in the normal-dysplasia-carcinoma sequence of the oral mucosa.

OBJECTIVE: We examined cell cycle and cell death biomarker trends with the normal-dysplasia-carcinoma sequence of the oral epithelia analyzing the pathological significance of a new biomarker, minichromosome maintenance 2 (MCM2). METHODS: This study analyzed 12 patients with normal oral epithelia, 69 with dysplasia, and 35 with squamous cell carcinoma (SCC); in 13 patients, SCCs were preceded by dysplasia. The sections were immunostained for MCM2, Ki-67, P53, P27(Kip1) and P21(CIP1/WAF1), and conducted by TUNEL methods. Western blot analysis of MCM2 was performed in the 4 human cultured oral SCCs, all of which showed the expression. RESULTS: Significantly higher labeling indices (LI; %) of MCM2, Ki-67, and P53, as well as lower LI of TUNEL indices (TI; %), P27, and P21 were noted in the SCCs than in the dysplasias. The 13 dysplasias developed SCC with significantly higher LI of MCM2 and P53, and lower LI of P21 than the other dysplasias (each p < 0.05). The LI of MCM2, P21 and the TI were not correlated with P53 expression. CONCLUSIONS: Oral dysplasia was characterized by lower cell proliferation and a higher frequency of cell death compared to SCCs. The higher LI of MCM2 and P53 and the lower LI of P21 might predict malignant transformation of oral dysplasia. MCM2 is regulated via a P53-independent pathway, and a useful biomarker of proliferating cells.     

埃兹蛋白在乳腺癌中的表达及其临床意义

目的 通过检测埃兹蛋白在浸润性乳腺癌、乳腺导管内癌及正常乳腺组织中的表达,探究埃兹蛋白在乳腺癌组织中的表达的临床意义。方法 随机选取南昌大学第一附属医院40例浸润性乳腺癌患者及32例乳腺导管内癌患者,另外选择同期来我院健康体检者22例。通过免疫组化链霉亲和素-过氧化物酶法（S-P）法分别检测埃兹蛋白在22例正常乳腺组织、32例乳腺导管内癌组织和40例浸润性乳腺癌组织中的表达,参照病理结果进行分析。结果 埃兹蛋白在40例浸润性乳腺癌的阳性表达率为72.50%、在32例乳腺导管内癌的阳性表达率为40.63%、在正常乳腺组织中的阳性表达率13.64%,浸润性乳腺癌中埃兹蛋白的表达高于其他两种组织,差异具有统计学意义（P＜0.05）;埃兹蛋白在G3期乳腺癌组织中的表达高于在G1~G2期乳腺癌组织中的表达,差异具有统计学意义（P＜0.05）;埃兹蛋白在淋巴结转移患者中的阳性表达率高于在无淋巴结转移的患者中的阳性表达率,差异统计学意义显著（P＜0.01）;埃兹蛋白在＜40岁的患者中的阳性表达率低于在年龄≥40岁的患者中的表达率,差异统计学意义显著（P＜0.01）;埃兹蛋白在PR阳性患者中的阳性表达率低于在PR阴性患者中的表达率,差异具有统计学意义（P＜0.05）;乳腺癌患者中埃兹蛋白的表达与组织学分级、腋窝淋巴结转移及年龄呈正相关（P＜0.05）,与PR呈负相关（P＜0.05）;埃兹蛋白在浸润性润腺癌中的表达与乳腺癌临床分期、脉管侵犯、肿瘤大小、患者月经状态以及Her-2、ER、Ki-67的表达无相关性（P＞0.05）。结论 埃兹蛋白在乳腺癌和正常乳腺组织中的表达不同,对判断乳腺肿瘤性质具有重要参考意义;此外,埃兹蛋白能够帮助判断乳腺癌的转移潜能和预后,可能启发乳腺癌新的靶向治疗。